Additionally, GsRb1 can be therapeutically valuable up to 24 h post-stroke, and it works well to increase the likelihood of long-term neurological recovery by activating the cyclic adenosine monophosphate/protein kinase A/cAMP response element-binding protein (cAMP/PKA/CREB) signaling pathway in vivo and encouraging axonal regeneration in the event of delayed stroke treatment (Yoshikawa et al., 2008; Gao et al., 2020). The gene discussed is CREB1; the disease is Stroke.